Biogened Dividends and Buybacks
Dividend criteria checks 1/6
Biogened is a dividend paying company with a current yield of 2.5% that is well covered by earnings.
Key information
2.5%
Dividend yield
n/a
Buyback Yield
| Total Shareholder Yield | n/a |
| Future Dividend Yield | n/a |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | zł0.500 |
| Payout ratio | 25% |
Recent dividend and buyback updates
Recent updates
Investors Give Biogened S.A. (WSE:BGD) Shares A 27% Hiding
Dec 06
Biogened (WSE:BGD) Takes On Some Risk With Its Use Of Debt
Nov 06A Piece Of The Puzzle Missing From Biogened S.A.'s (WSE:BGD) 25% Share Price Climb
Aug 28Impressive Earnings May Not Tell The Whole Story For Biogened (WSE:BGD)
Aug 22Investors Give Biogened S.A. (WSE:BGD) Shares A 37% Hiding
May 23Here's Why Biogened (WSE:BGD) Has A Meaningful Debt Burden
May 09Biogened's (WSE:BGD) Promising Earnings May Rest On Soft Foundations
Feb 21Is Biogened (WSE:BGD) A Risky Investment?
Feb 01Biogened S.A. (WSE:BGD) Looks Just Right With A 37% Price Jump
Feb 01We Think Biogened (WSE:BGD) Can Stay On Top Of Its Debt
Jun 30Biogened (WSE:BGD) Seems To Use Debt Quite Sensibly
Oct 08Is Biogened (WSE:BGD) A Risky Investment?
Jun 29Does Biogened (WSE:BGD) Have A Healthy Balance Sheet?
Mar 25These 4 Measures Indicate That Biogened (WSE:BGD) Is Using Debt Reasonably Well
Dec 09Biogened (WSE:BGD) Has A Somewhat Strained Balance Sheet
Jul 29Biogened (WSE:BGD) Seems To Use Debt Quite Sensibly
Apr 30Is Biogened (WSE:BGD) A Risky Investment?
Jan 24Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Whilst dividend payments have been stable, BGD has been paying a dividend for less than 10 years.
Growing Dividend: BGD's dividend payments have increased, but the company has only paid a dividend for 4 years.
Dividend Yield vs Market
| Biogened Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (BGD) | 2.5% |
| Market Bottom 25% (PL) | 3.0% |
| Market Top 25% (PL) | 8.6% |
| Industry Average (Pharmaceuticals) | 2.7% |
| Analyst forecast (BGD) (up to 3 years) | n/a |
Notable Dividend: BGD's dividend (2.5%) isn’t notable compared to the bottom 25% of dividend payers in the Polish market (3.05%).
High Dividend: BGD's dividend (2.5%) is low compared to the top 25% of dividend payers in the Polish market (8.65%).
Earnings Payout to Shareholders
Earnings Coverage: With its reasonably low payout ratio (25.2%), BGD's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: BGD is paying a dividend but the company has no free cash flows.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 08:56 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Biogened S.A. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|